@article {Perez-Cornago2021.10.05.21264556, author = {Aurora Perez-Cornago and Yashvee Dunneram and Eleanor L. Watts and Timothy J. Key and Ruth C. Travis}, title = {Adiposity and risk of prostate cancer death: a prospective analysis in UK Biobank and meta-analysis of published studies}, elocation-id = {2021.10.05.21264556}, year = {2021}, doi = {10.1101/2021.10.05.21264556}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Introduction The association of adiposity with prostate cancer specific mortality remains unclear. We examined how adiposity and its distribution relates to fatal prostate cancer by analysing data from UK Biobank, and conducting a dose-response meta-analysis to integrate existing prospective evidence. We also described the cross-sectional associations in UK Biobank of commonly used adiposity measurements with indices of adiposity estimated by imaging.Methods 218,246 men from UK Biobank who were free from cancer at baseline were included and participants were followed-up via linkage to health administrative datasets. Body mass index (BMI), total body fat percentage (using bioimpedance), waist circumference (WC) and waist-to-hip ratio (WHR) were collected at recruitment. Risk of dying from prostate cancer (primary cause) by the different adiposity measurements was estimated using multivariable-adjusted Cox proportional hazards models. Results from this and other prospective cohort studies were combined in a dose-response meta-analysis.Results In UK Biobank, 631 men died from prostate cancer over a mean follow-up of 11.5 years. The hazard ratios (HR) for prostate cancer death were 1.10 (95\% confidence interval=1.00-1.21) per 5 kg/m2 higher BMI, 1.03 (0.96-1.11) per 5\% increase in total body fat percentage, 1.09 (1.02-1.18) per 10 cm increase in WC, and 1.09 (1.02-1.16) per 0.05 increase in WHR. Our meta-analyses of prospective studies included 22,106 prostate cancer deaths for BMI, 642 for body fat percentage, 3,153 for WC and 1,611 for WHR, and the combined HRs for dying from prostate cancer for the increments above were 1.10 (1.08-1.13), 1.03 (0.96-1.11), 1.08 (1.04-1.12), and 1.07 (1.02-1.12), respectively. In up to 4,800 UK Biobank participants with magnetic resonance imaging and dual-energy X-ray absorptiometry, BMI and WC were strongly associated with imaging estimations of total and central adiposity (e.g. visceral fat, trunk fat), with associations marginally larger for WC. There might be \~{}1000 fewer prostate cancer deaths per year in the UK if the mean BMI in men was reduced by 5 kg/m2.Conclusion Overall, we found that men with higher total and central adiposity had similarly higher risks of prostate cancer death, which may be biologically driven or due to differences in detection. In either case, these findings provide further reasons for men to maintain a healthy body weight.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by Cancer Research UK Population Research Fellowship number C60192/A28516 and Cancer Research UK programme grant number C8221/A29017. AAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All individuals provided informed consent to participate and the study was approved by the National Information Governance Board for Health and Social Care and the National Health Service North West Multicentre Research Ethics Committee (reference number 06/MRE08/65).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated/and or analysed in the current study will be made available for bona fide researchers who apply to use the UK Biobank data set by registering and applying at http://www.ukbiobank.ac.uk/register-apply. http://www.ukbiobank.ac.uk/register-apply (BMI)Body Mass Index(CIs)confidence intervals(DXA)dual-energy X-ray absorptiometry(EPIC)European Prospective Investigation into Cancer and Nutrition(IARC)International Agency for Research on Cancer(ICD)International Statistical Classification of Diseases(IGF-I)insulin-like growth factor-I(HRs)hazard ratios(MRI)magnetic resonance imaging(NHS)National Health Service(PCa)prostate cancer(PSA)prostate-specific antigen(UK)United Kingdom(WC)waist circumference(WCRF)World Cancer Research Fund(WHR)waist to hip ratio}, URL = {https://www.medrxiv.org/content/early/2021/10/07/2021.10.05.21264556}, eprint = {https://www.medrxiv.org/content/early/2021/10/07/2021.10.05.21264556.full.pdf}, journal = {medRxiv} }